Compounds with 5-ht activity useful for controlling visual field loss
OwnerRobert J. Collier Jr, Mark R. Hellberg +1inventors
InventorsRobert J. Collier Jr, Mark R. Hellberg, Thomas R. Dean
Life of this patent
Estimating the term…
Abstract
Compounds with 5-HT1A agonist activity which are useful for controlling the visual field loss associated with glaucoma are disclosed.
Claims13
A method for controlling the visual field loss associated with glaucoma which comprises administering a pharmaceutically effective amount of a compound with 5-HT1A agonist activity.
The method of claim 2 wherein the compound is selected from the group consisting of:
- tandospirone, urapidil, ziprasidone, repinotan hydrochloride, xaliproden hydrochloride (SR-57746A), buspirone, flesinoxan, EMD-68843, DU-127090, gepirone, alnespirone, PNU-95666, AP-521, flibanserin, MKC-242, lesopitron, sarizotan hydrochloride, Org-13011, Org- 12966, E-5842, SUN-N4057, and 8-OH-DPAT1.
The use of a compound with 5-HT1A agonist activity for the manufacture of a medicament for controlling the visual field loss associated with glaucoma.
The use of a compound with 5-HT1A agonist activity for the manufacture of a medicament for providing neuroprotection to the neural retina.
Dependencies are inferred from the claim text.